US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Distillate Small/Mid Cash Flow ETF

30.96

+0.01270.04%

Post-market: 30.94-0.0223-0.07%16:05 EDT

Volume:4.78K

Turnover:148.00K

Market Cap:89.02M

PE:- -

High:31.04

Open:31.04

Low:30.94

Close:30.95

Loading ...

Overview Company News Filings

Achieve Life Sciences Reports Financial Results for Fourth Quarter and Year-End 2024 and Provides Update on the Cytisinicline Development Program

Theriva™ Biologics Reports Full-Year 2024 Operational Highlights and Financial Results

Achieve Life Sciences Announces Positive Outcome of Second Data Safety Monitoring Committee Review for the ORCA-OL Clinical Trial

ACHV: Long-Term Exposure Requirement Complete

Zacks Small Cap Research

Achieve Life Sciences Announces Critical Milestone Successfully Reached in ORCA-OL Cytisinicline Clinical Trial Required for NDA Submission

ACHV: Commercialization in Focus

Zacks Small Cap Research

Achieve Life Sciences Announces Completion of Enrollment in ORCA-OL Clinical Trial & Successful Outcome of the First Data Safety Monitoring Committee Meeting

Theriva Biologics’ SYN-004 receives positive DSMC review in Phase 1/2 trial

Nano-Cap Theriva Biologics' Investigational Drug For Transplant-Related Complication Shows Safety In Bone Marrow Transplant Patients

Theriva™ Biologics Announces Positive Outcome of Data and Safety Monitoring Committee (DSMC) Review in Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/DSMC/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"DSMC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"DSMC\",,,,,undefined,":{"symbol":"DSMC","market":"US","secType":"STK","nameCN":"Distillate Small/Mid Cash Flow ETF","latestPrice":30.9623,"timestamp":1746820800000,"preClose":30.9496,"halted":0,"volume":4776,"hourTrading":{"tag":"盘后","latestPrice":30.94,"preClose":30.9623,"latestTime":"16:05 EDT","volume":60,"amount":1856.4669,"timestamp":1746821113211},"delay":0,"floatShares":2875000,"shares":2875000,"eps":0,"marketStatus":"Market Closed","change":0.0127,"latestTime":"05-09 16:00:00 EDT","open":31.04,"high":31.04,"low":30.94,"amount":147998.5619,"amplitude":0.003231,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1747036800000},"marketStatusCode":7,"adr":0,"exchange":"ARCA","adjPreClose":30.9496,"sharesOutstanding":2875000,"nav":30.94,"aum":88952500,"dividendRate":0.014049,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":30.94,"preClose":30.9623,"latestTime":"16:05 EDT","volume":60,"amount":1856.4669,"timestamp":1746821113211},"volumeRatio":0.42926478711695487},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"DSMC\",,,,,undefined,":{"symbol":"DSMC","floatShares":2875000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.42926478711695487,"shares":2875000,"dividePrice":0.435,"high":31.04,"amplitude":0.003231,"preClose":30.9496,"low":30.94,"week52Low":26.93,"pbRate":"--","week52High":38.8374,"institutionHeld":0,"latestPrice":30.9623,"eps":0,"divideRate":0.014049,"volume":4776,"delay":0,"ttmEps":0,"open":31.04,"prevYearClose":34.9514,"prevWeekClose":30.8,"prevMonthClose":29.9474,"prevQuarterClose":31.5438,"fiveDayClose":30.8,"twentyDayClose":28.5418,"sixtyDayClose":34.3378},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"DSMC\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2518171779","title":"Achieve Life Sciences Reports Financial Results for Fourth Quarter and Year-End 2024 and Provides Update on the Cytisinicline Development Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2518171779","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518171779?lang=en_us&edition=fundamental","pubTime":"2025-03-11 19:30","pubTimestamp":1741692600,"startTime":"0","endTime":"0","summary":"Reiterates Planned Cytisinicline NDA Submission Expected at the End of Q2 2025 Company to Host Conference Call at 8:30 AM EDT Today, Tuesday, March 11, 2025 SEATTLE and VANCOUVER, British Columbia, Ma","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/11/3040444/0/en/Achieve-Life-Sciences-Reports-Financial-Results-for-Fourth-Quarter-and-Year-End-2024-and-Provides-Update-on-the-Cytisinicline-Development-Program.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DSMC"],"gpt_icon":0},{"id":"2517070113","title":"Theriva™ Biologics Reports Full-Year 2024 Operational Highlights and Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2517070113","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517070113?lang=en_us&edition=fundamental","pubTime":"2025-03-07 05:10","pubTimestamp":1741295400,"startTime":"0","endTime":"0","summary":"– Enrollment completed in VIRAGE Phase 2b clinical trial of VCN-01 in metastatic pancreatic ductal adenocarcinoma (PDAC); topline data expected in Q2 2025 – – VCN-01 development bolstered by FDA award","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/06/3038631/0/en/Theriva-Biologics-Reports-Full-Year-2024-Operational-Highlights-and-Financial-Results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CHMP","BK4087","DSMC"],"gpt_icon":0},{"id":"2510857314","title":"Achieve Life Sciences Announces Positive Outcome of Second Data Safety Monitoring Committee Review for the ORCA-OL Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2510857314","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510857314?lang=en_us&edition=fundamental","pubTime":"2025-02-10 21:30","pubTimestamp":1739194200,"startTime":"0","endTime":"0","summary":"No Safety Concerns Identified by DSMC in the ORCA-OL Long-Term Exposure Trial. Achieve Reiterates Planned Cytisinicline NDA Submission in Q2 2025. SEATTLE and VANCOUVER, British Columbia, Feb. 10, 2025  -- Achieve Life Sciences, Inc. , a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced that the Data Safety Monitoring Committee  has recently completed its second independent review of the ongoing ORCA-OL trial, evaluating long-term exposure of the novel 3 mg cytisinicline treatment dosing regimen in individuals who smoke cigarettes or vape nicotine.The ORCA-OL clinical trial is designed to satisfy the U.S. Food and Drug Administration’s  long-term exposure safety data requirements for cytisinicline’s potential approval. The FDA requested six-month safety exposure data from at least 300 participants who have been treated with cytisinicline to be included in th","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/achieve-life-sciences-announces-positive-133000683.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ACHV","BK4139","DSMC"],"gpt_icon":0},{"id":"2505277306","title":"ACHV: Long-Term Exposure Requirement Complete","url":"https://stock-news.laohu8.com/highlight/detail?id=2505277306","media":"Zacks Small Cap Research","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505277306?lang=en_us&edition=fundamental","pubTime":"2025-01-21 17:58","pubTimestamp":1737453480,"startTime":"0","endTime":"0","summary":"Achieve Life Sciences, Inc.  has been busy since its previous quarterly update, adding new board members and executives and completing the long-term portion of its ORCA OL study which will generate critical safety data to be used in the new drug application  for smoking cessation. The R&D team held the end of Phase II  meeting with the FDA to finalize the study design for the pivotal vaping trial. Management has shared its recent accomplishments at investor events including the Jefferies London Healthcare conference in November and the Piper Sandler Healthcare conference in December in New York. Management also participated in one-on-one meetings during the JP Morgan Healthcare Conference in San Francisco in January.The completed study will include safety data on at least 300 subjects that have received cumulative cytisinicline treatment for six months. After the 300 subjects complete six months of treatment, Achieve expects a three-month turnaround to collect the data, analyze it and ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/achv-long-term-exposure-requirement-095800350.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","ACHV","DSMC"],"gpt_icon":0},{"id":"2501201109","title":"Achieve Life Sciences Announces Critical Milestone Successfully Reached in ORCA-OL Cytisinicline Clinical Trial Required for NDA Submission","url":"https://stock-news.laohu8.com/highlight/detail?id=2501201109","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501201109?lang=en_us&edition=fundamental","pubTime":"2025-01-07 21:30","pubTimestamp":1736256600,"startTime":"0","endTime":"0","summary":"Over 300 Participants Have Completed Cumulative Six Months of Cytisinicline Treatment in the ORCA-OL Trial, Completing the Long-Term Exposure Requirement for NDA Submission  ORCA-OL Long-Term Exposure","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/07/3005424/0/en/Achieve-Life-Sciences-Announces-Critical-Milestone-Successfully-Reached-in-ORCA-OL-Cytisinicline-Clinical-Trial-Required-for-NDA-Submission.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DSMC"],"gpt_icon":0},{"id":"2482385977","title":"ACHV: Commercialization in Focus","url":"https://stock-news.laohu8.com/highlight/detail?id=2482385977","media":"Zacks Small Cap Research","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482385977?lang=en_us&edition=fundamental","pubTime":"2024-11-11 16:00","pubTimestamp":1731312000,"startTime":"0","endTime":"0","summary":"Achieve Life Sciences, Inc.  reported third quarter 2024 results in a November 7th press release distributed after the market's close. The company subsequently held a conference call discussing progress with the ORCA OL trial, pre-commercialization activities and the vaping indication. Form 10-Q was filed with the SEC pro-viding additional disclosures. Highlights during the third quarter and to date include addition of Achieve shares to the Russell 3000 and Russell Microcap Indices, a $20 million loan refinancing with Silicon Valley Bank, designation of cytisinicline as a Breakthrough Therapy in vaping, significant changes in management personnel and completion of enrollment in the ORCA-OL trial. Achieve's management and its representatives also presented at investor and scientific conferences. During the third quarter conference call, management refined its expected timeline and pathway forward to FDA approval of cytisinicline.Hand in hand with a greater focus on navigating the course","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/Giz7VL60PzwkmCR6C3jlLA--~B/aD01NjQ7dz0xMzE2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/scr.zacks.com/10bb0aef1a6262e4fb9a7094a2ba6357","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/Giz7VL60PzwkmCR6C3jlLA--~B/aD01NjQ7dz0xMzE2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/scr.zacks.com/10bb0aef1a6262e4fb9a7094a2ba6357"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/achv-commercialization-focus-080000558.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","ACHV","DSMC"],"gpt_icon":0},{"id":"2474207714","title":"Achieve Life Sciences Announces Completion of Enrollment in ORCA-OL Clinical Trial & Successful Outcome of the First Data Safety Monitoring Committee Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2474207714","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2474207714?lang=en_us&edition=fundamental","pubTime":"2024-10-10 20:00","pubTimestamp":1728561600,"startTime":"0","endTime":"0","summary":"SEATTLE and VANCOUVER, British Columbia, Oct.  10, 2024  (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company dedicated to the global development and com","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/10/10/2961265/0/en/Achieve-Life-Sciences-Announces-Completion-of-Enrollment-in-ORCA-OL-Clinical-Trial-Successful-Outcome-of-the-First-Data-Safety-Monitoring-Committee-Meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DSMC"],"gpt_icon":0},{"id":"2473792123","title":"Theriva Biologics’ SYN-004 receives positive DSMC review in Phase 1/2 trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2473792123","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2473792123?lang=en_us&edition=fundamental","pubTime":"2024-10-05 15:40","pubTimestamp":1728114016,"startTime":"0","endTime":"0","summary":"Theriva Biologics announced a positive outcome from the Data and Safety Monitoring Committee – DSMC – review of results from the second Cohort of i...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/theriva-biologics-syn-004-receives-positive-dsmc-review-in-phase-1-2-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/theriva-biologics-syn-004-receives-positive-dsmc-review-in-phase-1-2-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","TOVX","DSMC"],"gpt_icon":0},{"id":"2472612378","title":"Nano-Cap Theriva Biologics' Investigational Drug For Transplant-Related Complication Shows Safety In Bone Marrow Transplant Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2472612378","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2472612378?lang=en_us&edition=fundamental","pubTime":"2024-10-03 22:45","pubTimestamp":1727966746,"startTime":"0","endTime":"0","summary":"On Thursday, Theriva Biologics, Inc.  revealed the outcome of the Data and Safety Monitoring Committee  review of results from the second cohort of its Phase 1b/2a trial of SYN-004  in allogeneic hematopoietic cell transplant  recipients to prevent acute graft-versus-host disease .Allogeneic hematopoietic cell transplant is a type of bone marrow transplant.GVHD is a common complication when transplanted donor cells recognize the recipient’s tissues as foreign and attack them.As per data from Benzinga Pro, the stock is trading higher on a strong session volume of 18.61 million compared to an average volume of 671.35K.The study is ongoing and remains blinded; however, key findings from blinded data for Cohort 2 are included below:. Adverse events  and serious adverse events  observed in cohort 2 were typical of those observed in allo-HCT patients, and no AEs or SAEs were related to the study drug treatment.A total of 15 SAEs were reported among ten patients, with the most common SAE bein","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/TLfofvNAlZgjetpEghFSEQ--~B/aD01NTM7dz05ODM7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/c1206008ea504ac36ecb7e18ef64697a","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/TLfofvNAlZgjetpEghFSEQ--~B/aD01NTM7dz05ODM7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/c1206008ea504ac36ecb7e18ef64697a"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/nano-cap-theriva-biologics-investigational-144546836.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","TOVX","DSMC"],"gpt_icon":0},{"id":"2472694012","title":"Theriva™ Biologics Announces Positive Outcome of Data and Safety Monitoring Committee (DSMC) Review in Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients","url":"https://stock-news.laohu8.com/highlight/detail?id=2472694012","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2472694012?lang=en_us&edition=fundamental","pubTime":"2024-10-03 20:00","pubTimestamp":1727956800,"startTime":"0","endTime":"0","summary":"DSMC has reviewed the safety and pharmacokinetic data from Cohort 2 and recommended that the study proceed to enroll patients into Cohort 3ROCKVILLE, Md., Oct.  03, 2024  (GLOBE NEWSWIRE) -- Theriva B","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/10/03/2957647/0/en/Theriva-Biologics-Announces-Positive-Outcome-of-Data-and-Safety-Monitoring-Committee-DSMC-Review-in-Phase-1b-2a-Clinical-Trial-of-SYN-004-ribaxamase-in-Allogeneic-Hematopoietic-Cel.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMR","BK4006","DSMC","BK4585","BK4588"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":10,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/DSMC\",params:#limit:5,,,undefined,":[{"date":"2025-03-26","symbol":"DSMC","amount":0.075599,"announcedDate":"2025-03-25","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-26","defaultRemindTime":1742995800000,"name":"Distillate Small/Mid Cash Flow ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-03-27","payableDate":"2025-03-26","currency":"USD","dateTimestamp":1742961600000,"payDate":"2025-03-27"},{"date":"2024-12-27","symbol":"DSMC","amount":0.16,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-27","defaultRemindTime":1735309800000,"name":"Distillate Small/Mid Cash Flow ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-30","payableDate":"2024-12-27","currency":"USD","dateTimestamp":1735275600000,"payDate":"2024-12-30"},{"date":"2024-09-25","symbol":"DSMC","amount":0.09517,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-09-25","defaultRemindTime":1727271000000,"name":"Distillate Small/Mid Cash Flow ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-09-26","payableDate":"2024-09-25","currency":"USD","dateTimestamp":1727236800000,"payDate":"2024-09-26"},{"date":"2024-06-26","symbol":"DSMC","amount":0.10473,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-06-26","defaultRemindTime":1719408600000,"name":"Distillate Small/Mid Cash Flow ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-06-27","payableDate":"2024-06-26","currency":"USD","dateTimestamp":1719374400000,"payDate":"2024-06-27"},{"date":"2024-03-20","symbol":"DSMC","amount":0.098436,"announcedDate":"2024-03-19","type":"dividend","market":"US","newRecordDate":"2024-03-21","defaultRemindTime":1710941400000,"name":"Distillate Small/Mid Cash Flow ETF","recordDate":"2024-03-22","payableDate":"2024-03-21","currency":"USD","dateTimestamp":1710907200000,"payDate":"2024-03-22"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"DSMC\",market:\"US\",,,undefined,":[{"executeDate":"2022-12-28","recordDate":"2022-12-29","paymentDate":"2022-12-30","value":0.073726,"currency":"USD"},{"executeDate":"2023-03-22","recordDate":"2023-03-23","paymentDate":"2023-03-24","value":0.069972,"currency":"USD"},{"executeDate":"2023-06-21","recordDate":"2023-06-22","paymentDate":"2023-06-23","value":0.089299,"currency":"USD"},{"executeDate":"2023-09-20","recordDate":"2023-09-21","paymentDate":"2023-09-22","value":0.086071,"currency":"USD"},{"executeDate":"2023-12-27","recordDate":"2023-12-28","paymentDate":"2023-12-29","value":0.107254,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"DSMC\",market:\"US\",delay:false,,,undefined,":{}}}